<DOC>
	<DOCNO>NCT01915537</DOCNO>
	<brief_summary>A prospective , multi-centric , cohort study observe efficacy difference intensive classic DMARDs Infliximab ( IFX ) methotrexate ( MTX ) treatment sever rheumatoid arthritis ( RA ) 28 joint disease activity score &gt; 5.1 ( DAS28 &gt; 5.1 ) patient poor prognostic factors.Primary objective compare difference clinical remission rate classic DMARDs Infliximab MTX treatment severe RA patient poor prognostic factor week 30 .</brief_summary>
	<brief_title>Infliximab Classic DMARDs Rheumatoid Arthritis Patients</brief_title>
	<detailed_description>Primary objective compare difference clinical remission rate classic conventional disease-modifying antirheumatic drug ( DMARDs ) Infliximab methotrexate ( MTX ) treatment severe RA patient poor prognostic factor week 30 . Secondary objective compare difference laboratory measurement , clinical remission rate , function score imageological evaluation classic DMARDs Infliximab MTX treatment severe RA patient poor prognostic factor week 14 , 30 , 54 102 . Infliximab arm：Infliximab MTX treatment : Infliximab 3mg/kg week 0 , 2 , 6 every 8 week , MTX &gt; 7.5mg per week . To observe result week 14 , 30 , 54 102 6 time IFX treatment . It recommend continue receive IFX treatment remission period time good economic condition patient receive MTX hydroxychloroquine ( HCQ ) leflunomide ( LEF ) poor economic condition patient . Classic DMARDs treatment arm： Classic DMARDs treatment combination 2 3 drug , 2-drugs combination MTX LEF Thunder God Vine , 3-drugs combination MTX HCQ LEF Thunder God Vine total 30 week . Effective dose : MTX : 10-15mg per week ; LEF : 20mg per day ; HCQ : 200-400 mg per day ; Thunder God Vine : 40-60 mg per day ; It recommend maintain regimen MTX HCQ LEF remission period time . Study divide three stage First stage : day -7 0 1 . Sign informed consent ; 2 . Examine verify inclusion exclusion criterion ; 3 . Collect data demographic characteristic , history present illness , sign symptom , history previous illness concomitant medicine , personal history , allergic history , injury surgery history ; 4 . Data laboratory examination : Rheumatoid Factor ( RF ) , anti citrullinated protein antibody ( ACPA ) ; 5 . Safety data : vital sign , blood routine examination , biochemical test ; 6 . Efficacy data : Erythrocyte Sedimentation Rate ( ESR ) , C Reactive Protein ( CRP ) , 28 joint disease activity score ( DAS28 score ) , Simplified disease activity index ( SDAI ) score , American College Of Rheumatology ( ACR ) /European League Against Rheumatism ( EULAR ) remission , Sharp van der Heijde scoring ( SHARP ) score , Magnetic Resonance Imaging ( MRI ) score , Health Assessment Questionnaire ( HAQ ) score ; Second stage : week 0 week 30 , follow-up duration I The subject randomize assigned achieve experimental control treatment 30 week follow week 2 , 6 , 14 , 22 30 . 1 . The follow item week 2 week 22 : sign symptom , ESR , CRP ; 2 . The follow item week 6 : sign symptom , blood routine examination , biochemical test , ESR , CRP ; 3 . The follow item week 14 : sign symptom , ESR , CRP , DAS28 score , SDAI score , ACR/EULAR remission , SHARP score , MRI score , HAQ score ; 4 . The follow item week 30 : sign symptom , RF , ACPA , blood routine examination , biochemical test , ESR , CRP , DAS28 score , SDAI score , ACR/EULAR remission , SHARP score , MRI score , HAQ score . Third stage : Week 30 102 , follow-up duration II After 30 week treatment subject 72 week follow-up duration , follow conduct week 38 , 46 , 54 102 . 1 . The follow item week 38 46 : sign symptom , ESR , CRP ; 2 . The follow item : sign symptom , blood routine examination , biochemical test , ESR , CRP , DAS28 score , ACR/EULAR remission , SHARP score , MRI score , HAQ score ; 3 . The follow item week 102 : sign symptom , RF , ACPA , blood routine examination , biochemical test , ESR , CRP , DAS28 score , SDAI score , ACR/EULAR remission , SHARP score , MRI score , HAQ score .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>1 . Able willing provide write informed consent comply study protocol 2 . Age 18 70 year old 3 . To accord diagnostic criterion ACR/EULAR 2010 course disease less 2 year ; 4 . Active RA , DAS28 score 5.1 5 . At least one poor prognostic factor include : ( 1 ) functional limitation , ( 2 ) extraarticular manifestation , ( 3 ) positive RF AntiCyclic Citrullinated Peptide ( CCP ) antibody , ( 4 ) X ray confirm bone erosion . 1 . Received Infliximab biologics treatment previously ; 2 . Abnormal liver function , level alanine aminotransferase ( ALT ) aspartate amino transferase ( AST ) high 3 time upper limit normal ( ULN ) ; 3 . Renal dysfunction , level serum creatinine high 1.5 time ULN ; 4 . Receive live virus bacterial vaccination currently 4 week recruitment study ; 5 . Previously affect tuberculosis positive tuberculin test result ; 6 . Has history lymphoproliferative disease lymphoma suspect lymphoproliferative disease sign symptoms lymphadenectasis posterior cervical triangle , interclavicular supratrochlear , splenomegaly ( 2 cm rib ) ; 7 . History multiple sclerosis demyelinating diseases central nervous system ; 8 . Be allergic experimental drug serious allergic constitution ; 9 . Malignancies exclude cure skin basal cell carcinoma carcinoma situ cervix ; 10 . Systemic active infection , HIV infection active Hepatitis B Hepatitis B virus carrier ; 11 . With serious medical disease cardiac insufficiency ( ) , myocardial ischemia , serious arrhythmia , renal insufficiency , serious liver dysfunction , significant hematological system disease , hypercortisolism , uncontrollable hypertension diabetes mellitus ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>poor prognosis</keyword>
	<keyword>severe RA</keyword>
	<keyword>infliximab</keyword>
</DOC>